Published in J Antimicrob Chemother on May 25, 2010
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog (2012) 1.11
In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother (2011) 1.10
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malar J (2010) 1.05
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Malar J (2011) 0.96
Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin. Antimicrob Agents Chemother (2012) 0.92
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. Malar J (2013) 0.92
Whole genome re-sequencing identifies a mutation in an ABC transporter (mdr2) in a Plasmodium chabaudi clone with altered susceptibility to antifolate drugs. Int J Parasitol (2010) 0.90
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Malar J (2012) 0.90
The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates. Antimicrob Agents Chemother (2012) 0.86
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. Malar J (2013) 0.84
Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast. Malar J (2012) 0.83
Inhibitory effects of pepstatin A and mefloquine on the growth of Babesia parasites. Am J Trop Med Hyg (2012) 0.81
Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. Sci Rep (2016) 0.75
In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum. Malar J (2014) 0.75
Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis (2011) 7.42
Combination of malaria vector control interventions in pyrethroid resistance area in Benin: a cluster randomised controlled trial. Lancet Infect Dis (2012) 4.44
Prognostic value of thrombocytopenia in African children with falciparum malaria. Am J Trop Med Hyg (2002) 3.78
Protective efficacy of lambda-cyhalothrin treated nets in Anopheles gambiae pyrethroid resistance areas of Côte d'Ivoire. Am J Trop Med Hyg (2005) 2.89
Incidence of tick-borne relapsing fever in west Africa: longitudinal study. Lancet (2006) 2.77
Towards high-throughput molecular detection of Plasmodium: new approaches and molecular markers. Malar J (2009) 2.76
Sub-microscopic malaria cases and mixed malaria infection in a remote area of high malaria endemicity in Rattanakiri province, Cambodia: implication for malaria elimination. Malar J (2010) 2.75
Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med (2007) 2.54
Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am J Trop Med Hyg (2006) 2.34
Combating malaria in Africa. Trends Parasitol (2002) 1.98
Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg (2006) 1.97
Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis (2010) 1.89
Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol (2006) 1.74
Highly focused anopheline breeding sites and malaria transmission in Dakar. Malar J (2009) 1.63
Antibody response against saliva antigens of Anopheles gambiae and Aedes aegypti in travellers in tropical Africa. Microbes Infect (2007) 1.63
Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J (2011) 1.63
Malaria infection and disease in an area with pyrethroid-resistant vectors in southern Benin. Malar J (2010) 1.59
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother (2009) 1.59
Social and environmental malaria risk factors in urban areas of Ouagadougou, Burkina Faso. Malar J (2009) 1.57
Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. Am J Trop Med Hyg (2007) 1.55
Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013. Malar J (2014) 1.49
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One (2007) 1.44
Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J (2011) 1.40
Implication of haematophagous arthropod salivary proteins in host-vector interactions. Parasit Vectors (2011) 1.39
Malaria transmission in Dakar: a two-year survey. Malar J (2008) 1.38
An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg (2006) 1.35
Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother (2007) 1.33
Changing malaria epidemiology and diagnostic criteria for Plasmodium falciparum clinical malaria. PLoS One (2012) 1.33
Comparative performances, under laboratory conditions, of seven pyrethroid insecticides used for impregnation of mosquito nets. Bull World Health Organ (2003) 1.33
Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiveness in the villages of Dielmo and Ndiop, Senegal. Malar J (2010) 1.31
Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother (2008) 1.29
Genetic structure of Plasmodium falciparum and elimination of malaria, Comoros archipelago. Emerg Infect Dis (2010) 1.27
Malaria incidence in relation to rice cultivation in the irrigated Sahel of Mali. Acta Trop (2004) 1.25
Spatial heterogeneity and temporal evolution of malaria transmission risk in Dakar, Senegal, according to remotely sensed environmental data. Malar J (2010) 1.25
Molecular detection of Bartonella quintana, B. Elizabethae, B. Koehlerae, B. Doshiae, B. Taylorii, and Rickettsia felis in rodent fleas collected in Kabul, Afghanistan. Am J Trop Med Hyg (2006) 1.24
Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. Malar J (2013) 1.23
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother (2005) 1.23
Possible autochthonous malaria from Marseille to Minneapolis. Emerg Infect Dis (2007) 1.22
The use of remotely sensed environmental data in the study of malaria. Geospat Health (2011) 1.22
Genetic determination and linkage mapping of Plasmodium falciparum malaria related traits in Senegal. PLoS One (2008) 1.20
Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. J Antimicrob Chemother (2011) 1.19
Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar J (2010) 1.19
Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis (2010) 1.18
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother (2013) 1.15
Antibody responses to several malaria pre-erythrocytic antigens as a marker of malaria exposure among travelers. Am J Trop Med Hyg (2006) 1.13
Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein. Antimicrob Agents Chemother (2011) 1.12
Quinine-resistant malaria in traveler returning from Senegal, 2007. Emerg Infect Dis (2010) 1.11
A multiplex assay for the simultaneous detection of antibodies against 15 Plasmodium falciparum and Anopheles gambiae saliva antigens. Malar J (2010) 1.11
In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother (2011) 1.10
Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg (2011) 1.10
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 1.10
Diagnostic criteria and risk factors for Plasmodium ovale malaria. J Infect Dis (2002) 1.10
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother (2009) 1.10